Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era

INTRODUCTION: Induction therapy for multiple myeloma is traditionally capped at 6 cycles of lenalidomide due to concerns that longer treatment compromises the ability to collect sufficient stem cells for autologous stem cell transplantation (ASCT). However, during the COVID-19 pandemic, many of our...

Descripción completa

Detalles Bibliográficos
Autores principales: Rybinski, Brad, Rapoport, Aaron P, Badros, Ashraf Z., Hardy, Nancy, Kocoglu, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958842/
https://www.ncbi.nlm.nih.gov/pubmed/35504807
http://dx.doi.org/10.1016/j.clml.2022.03.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958842/
https://www.ncbi.nlm.nih.gov/pubmed/35504807
http://dx.doi.org/10.1016/j.clml.2022.03.013

Ejemplares similares